Loading
institutionsInstitution
IRCCS Humanitas Research Hospital
A Milan research hospital known for Alberto Mantovani's work on tumour-associated macrophages and for stereotactic radiotherapy and liver cancer trials.
Also called: Humanitas Cancer CenterIstituto Clinico Humanitas
Overview
Humanitas Research Hospital, founded in 1996 in Rozzano, is a private IRCCS teaching hospital with its own Humanitas University. Alberto Mantovani, its scientific director, established the concept of cancer-related inflammation and the role of tumour-associated macrophages, complement and pentraxin 3 in tumour progression. The Humanitas Cancer Center under Armando Santoro has been a major site for hepatocellular carcinoma and biliary cancer trials, including with Lorenza Rimassa, and Marta Scorsetti's radiotherapy department is a leader in stereotactic body radiotherapy for oligometastatic disease. The hospital also runs haematology, thoracic and colorectal surgery and an early-phase unit, and holds OECI accreditation.
Location
Rozzano (Milan), IT
Type
hospital · Humanitas University
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#105 · 38 points (0 Newsweek + 0 NCI + 38 from 19 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.
Matched to IRCCS Humanitas Research Hospital, including child institutions. 1,031 works · 10,720 citations · 65% open access · 13% clinical trials · 5% reviews.
Oncology works per year
1862022
2242023
2152024
2402025
1662026
Most works
- Cesare Hassan96 works
- Alessandro Zerbi83 works
- Alessandro Repici81 works
- Armando Santoro75 works
- Marco Spadaccini59 works
- Antonino Spinelli58 works
- Silvia Carrara58 works
- Stéfania Bramanti47 works
- Giovanni Capretti46 works
- Antonio Facciorusso43 works
Most cited
- Tumour-associated macrophages and innate immunity
- Hepatobiliary oncology trials
- Stereotactic body radiotherapy
- Haematology
- Early-phase trials
Armando Santoro
Head of the Medical Oncology and Hematology Unit; Full Professor of Medical Oncology, Humanitas University
Medical oncologyLymphomaHepatocellular carcinoma
Veteran Italian medical oncologist who leads oncology and haematology at Humanitas and has co-authored major trials in lymphoma, liver cancer and novel targeted drugs.
Domenica Lorusso
Director of Gynaecological Oncology, Humanitas San Pio X and Humanitas University, Milan
Cervical cancerEndometrial cancerOvarian cancer
Led KEYNOTE-A18, which showed adding pembrolizumab to chemoradiotherapy improves survival in locally advanced cervical cancer.
Riccardo Bui
Representative of IRCCS Humanitas Research Hospital to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
Riccardo Bui represents IRCCS Humanitas Research Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Italy.
Simona Sancini
Medical Director (Direttore Sanitario)
Hospital managementClinical governance
Medical Director of IRCCS Humanitas Research Hospital in Rozzano (Milan), responsible for clinical governance across the hospital and its cancer center.
Similar pages
- PersonMario Taccolini
Shares Fondazione Poliambulanza, Organisation of European Cancer Institutes.
- PersonAlessandro Venturi
Shares Fondazione IRCCS Policlinico San Matteo, Organisation of European Cancer Institutes.
- IdeaTurn one tumour into a vaccine to treat all the others
Shares Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, SBRT / SABR (stereotactic radiotherapy), Diffuse large B-cell lymphoma.
- IdeaBlock the complement signal that recruits tumour-protecting cells
Shares Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- IdeaA neutral platform trial for radiotherapy plus immunotherapy combinations
Shares Oligometastatic disease, Durvalumab, SBRT / SABR (stereotactic radiotherapy), IMRT / IGRT (modern external beam).
- IdeaBispecific antibodies that engage macrophages instead of T cells
Shares CAR-NK & CAR-macrophage, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment.
- TermImmuno-oncology (IO) and checkpoint blockade
Shares Hot vs cold tumours, Atezolizumab, Durvalumab, Immune checkpoint inhibitors.
- Key paperCoussens and Werb 2002: inflammation and cancer
Shares Balkwill and Mantovani 2001: inflammation and cancer, back to Virchow?, Hepatocellular carcinoma, Immune checkpoint inhibitors.
cancers
fronts
technologies
drugs
ApprovedMonoclonal antibody (anti-PD-L1)
Atezolizumab · Tecentriq / Tecentriq Hybreza (SC)
ApprovedMonoclonal antibody (anti-PD-L1)
Durvalumab · Imfinzi